Instil Bio
34 hedge funds and large institutions have $81.3M invested in Instil Bio in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital inflows, than outflows
Capital inflows: $10.2M | Capital outflows: $10.7M
3.44% less ownership
Funds ownership: 70.9% → 67.46% (-3.4%)
11% less funds holding
Funds holding: 38 → 34 (-4)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.81M |
| 2 |
Millennium Management
New York
|
+$2.25M |
| 3 |
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.91M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.14M |
| 5 |
LPL Financial
San Diego,
California
|
+$855K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.4M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.85M |
| 3 |
Renaissance Technologies
New York
|
-$1.47M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.24M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.2M |
TIL Hedge Fund Activity: Q3 2025 in Review
34 of the 7,652 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q3 2025, worth a combined $81.3M — down 16% from $96.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TIL and 5 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was BML Capital Management, adding an estimated $2.81M. The largest seller was Goldman Sachs, exiting entirely with an estimated $3.4M sold.
- 34 institutional investors held Instil Bio (TIL) as of Q3 2025, down from 38 in Q2 2025.
- Funds reported $81.3M of Instil Bio stock for Q3 2025, down 16% quarter-over-quarter.
- 5 funds opened new Instil Bio positions in Q3 2025 and 9 closed out, a net change of -4 holders.
- The largest Instil Bio buyer in Q3 2025 was BML Capital Management, an estimated $2.81M added.
- The largest Instil Bio seller in Q3 2025 was Goldman Sachs, an estimated $3.4M sold.
Based on aggregated 13F filings for Q3 2025.